Floatz logo

Hycamtin

Rectal Neoplasms

H. Lee Moffitt Cancer Center and Research InstitutePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Rectal Neoplasms cohort.

Asset / SponsorPhaseRating
Eloxatin
Chongqing University Cancer Hospital
Phase 3BB
PROPOFOL
Uppsala University
Phase 4BB
FLUOROURACILUM
Pei-Rong Ding
Phase 3BB
Ertapenem
University of Ulm
Phase 4BB
Sevoflurane
Uppsala University
Phase 4BB

View all 46 →

Same molecule, other indications

Hycamtin is also rated in:

primary peritoneal carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
non-small cell lung carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →